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Background: Obsessive-compulsive disorder (OCD) is a common behavioral disorder
among adolescents and children. The selective serotonin reuptake inhibitors (SSRIs) are
the first pharmacological choice for this condition due to mild adverse effect profile.
Objective: This systematic review was performed to evaluate the efficacy of SSRI for
OCD in adolescents and children.
Methods: Search terms were entered into PubMed, PsycINFO, Scopus, CINAHL, and
Google Scholar. The included studies were randomized, placebo-controlled trials of
SSRIs conducted in populations of children and adolescents younger than 18 years.
Change from baseline Children’s Yale-Brown Obsessive-Compulsive Scale (CY-BOCS),
end-treatment CY-BOCS with respective SD, and response and remission rates were
collected for continuous and dichotomous outcome assessment, respectively. Cochrane
Rev Man software was used for meta-analyses, providing Forest plots where applicable.
Results: SSRIs were superior to placebo with a small effect size. There was no additional
benefit of combination treatment over cognitive behavioral therapy (CBT) alone, but CBT
added substantial benefit to SSRI monotherapy. Fluoxetine and sertraline appear to be
superior to fluvoxamine.
Conclusion: The results of current systematic review and meta-analysis support the
existing National Institute for Health and Care Excellence (NICE) guidelines for choosing
CBT as first line of treatment and substituting it with SSRI, depending on patient
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preference. Adding CBT to current SSRI treatment is effective for non-responders and
partial responders, but adding SSRI to ongoing CBT does not prove beneficial. The SSRIs
have different effectiveness, and their relative efficacy remains to be investigated.
Keywords: selective serotonin reuptake inhibitors, obsessive-compulsive disorder, adolescents, children,
cognitive behavioral therapy

INTRODUCTION

to the pre-existing classes of anti-depressants, i.e., TCAs and
monoamine oxidase inhibitors (MAOIs). Being selective in
nature of their action, SSRIs had a much more favorable sideeffect profile (especially regarding that of arrhythmias and QT
prolongation which were absent with the latter agents), easier
dose titration, remarkable margin of safety when considering
overdoses, and thus overall were better tolerated and adhered to
by the populations with psychiatric and mood disorders (10).
A meta-analysis suggested clomipramine to be more effective
compared with SSRI for the treatment of OCD in children (11).
That said, direct comparisons of clomipramine and SSRI have
not shown any superiority for any of the two drugs for treating
OCD in adults (12–15). There has not been a single study
comparing clomipramine to SSRI in a head to head design for
treating OCD in children, and the claims of the former being
more efficacious than the latter cannot be given considerable
weight until proven otherwise.
The commonly held opinion is that cognitive behavioral
therapy (CBT) should be the first line of treatment for OCD in
children and adolescents. This approach has also been endorsed
by the existing clinical guidelines (16, 17) and has a considerable
base of evidence. A systematic review of 13 randomized controlled
trials (RCTs) assessing the treatment options for OCD (18)
pointed out to the place and efficacy of CBT for the management
of OCD in children and adolescents, but the comparisons were
made to waitlist and placebo treatment, and not to other available
active options.
Thus, the current role of SSRIs in managing OCD in
adolescents and children remains at least under-investigated.
We have undertaken this review to address some of the gaps
concerning SSRI treatment, as described more thoroughly below.
To be familiar with the ground of research on OCD treatment,
the reader is humbly referred to the previously conducted
systematic reviews and meta-analyses concerning the abovementioned issues (7, 11, 19–23).

Obsessive-compulsive disorder (OCD) is a chronic debilitating
condition that is associated with recurrent and persistent thoughts
and the compulsions to suppress them with certain excessive
and repetitive behaviors. For about half of the diagnosed cases,
the onset of OCD takes place in childhood or adolescence (1).
Compared with adults, children are more likely to demonstrate
the evolution of clinical manifestations and the symptoms wax
and wane as they grow (2, 3).
Currently, the diagnosis is based on internationally accepted
classification systems, namely Diagnostic and Statistical Manual
of Mental Disorders in its fifth edition (DSM 5) in the United
States and, less frequently, ICD 10 criteria elsewhere. In addition
to diagnosing, the severity of the condition is assessed and
documented using validated scales, such as Children’s YaleBrown Obsessive-Compulsive Scale (CY-BOCS) for children and
adolescents, which is a modification of the original Yale-Brown
Obsessive-Compulsive Scale (Y-BOCS) used for adults.
Medications and psychotherapy or a combination of both are
commonly used to treat patients with OCD. The only currently
available treatment options for OCD are either medication
or psychotherapy or the combination thereof (4, 5), the latter
being chosen for more severe, refractory to treatment and
comorbid cases.
Treatment with clomipramine, a tricyclic antidepressant
(TCA) that inhibits reuptake of serotonin, was the first option
demonstrated to be effective at reducing OCD symptoms (6),
and this was later confirmed in a 2003 meta-analysis (7) for the
pediatric population. Although clomipramine is an effective
option, it cannot be used as a first-line agent for treating OCD in
children and adolescents due to its overburdened adverse effect
profile (8, 9). Although it most commonly causes a combination
of minor cholinergic symptoms, such as sedation, bothersome
xerostomia, constipation, and urinary retention, and even
more, severe events like seizures and cardiovascular effects,
such as orthostatic hypotension, tachy- and bradyarrhythmias,
ventricular fibrillation, and prolonged QT are well documented.
In some of the devastating cases, sudden cardiac death in youth
is attributed to such effects. Thus, a better tolerated and safer
alternative has been sought to replace clomipramine as the more
appropriate pharmaceutical candidate. The selective serotonin
reuptake inhibitors (SSRIs) seem to efficiently fill in that role.
Approved by the FDA at the end of 1978, fluoxetine (Prozac)
was the first agent marketed as an SSRI, and its use has once and
for all established the role of serotonin (5-HT) in the pathogenesis
of psychiatric disorders. SSRIs were in many aspects’ superior
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THE RATIONALE FOR THIS REVIEW
The current systematic review was undertaken for the following
reasons. There have been a number of both remote and recent
systematic reviews and meta-analyses on various treatment
options for OCD in adolescents and children (see above),
including CBT, SRI, and the combination thereof, but none
has specifically addressed the role of SSRIs, and comparisons
between different SSRIs are lacking as well. Thus, we have decided
to review the existing literature regarding treatments that utilize
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only SSRIs as the medication of intervention for treatment of
OCD in adolescents and children.

was attempted for different SSRIs using the I2 statistic in generic
inverse variance analysis.

AIMS AND OBJECTIVES

RESULTS

The purpose of the current systematic review and meta-analysis
was to investigate the efficacy of SSRIs in forms of monotherapy
or in combination treatment with CBT for the management of
OCD in adolescents and children and compare the effectiveness
of different SSRIs.

Search Results

The search of databases produced 3,429 results. Following the
exclusion of duplicates, another 2,241 studies were excluded
during the title and abstract screening. This resulted in 136
articles, the full paper texts of which were retrieved and reviewed.
The search through citations did not reveal any additional relevant
sources. Twelve articles, which met the inclusion criteria, were
eventually included (Figure 1).

METHODS
Search for Publications

Characteristics of Included Studies

The authors (AK and VK) searched the PubMed, PsycINFO,
Scopus, CINAHL, and Google Scholar databases using the
following keywords: (“treatment” OR “therapy” OR “SSRI” OR
“Selective Serotonin Reuptake Inhibitors” OR “sertraline” or
“fluoxetine” OR “fluvoxamine “ OR “paroxetine” OR “citalopram”
OR “escitalopram”) AND (“OCD” OR “obsessive compulsive
disorder” OR “obsessional compulsive disorder”) AND (“children”
OR “adolescents”), for citations from first available index date to
January 1, 2018. The authors also manually searched the references
from relevant systematic reviews and meta-analyses for additional
citations that could have been missed through the initial search.
Two authors (AK and SD) then independently screened the
titles and abstracts for the exclusion of irrelevant studies. The full
papers were then obtained to verify for inclusion eligibility. At
each step, the results were compared between the researchers and
any discrepancies were handled with means of discussion. Any
disagreements were resolved by involving the third independent
author (RA).

We have included 12 RCTs (published from 1992 to 2015) in our
systematic review with a total number of 958 patients. Patients’
age ranged from 6 to 18 years with reported means ranging
from 11 ± 3 to 15 ± 2.4 years. Two studies (18, 24) implemented
Independent Medical Examination (IME), and seven studies
used intention to treat (ITT) analysis. Only three studies (25–27)
did not proceed with the ITT method due to high rate of trial
completion (92.9%, 100%, and 97.5%, respectively). The pre-trial
treatment of participants was markedly heterogeneous, wherever
reported. One of the trials was of a crossover design (25), and
only data extracted from initial 8 weeks were included in this
review (the second phase had marked dropout rates). One study
(28) directly (without a placebo arm) compared the two SSRIs
(fluoxetine versus citalopram), and the extracted data were only
used for evaluating the efficacy of different SSRIs.
All included studies reported primary outcome measures using
CY-BOCS or calculations based on it. Ten studies reported rates
of response to treatment, the definition of which varied across
studies: 4, 2, and 1 studies defined response as 25%, 30%, and 40%
decrease from baseline CY-BOCS, respectively, one study used endtreatment CY-BOCS ≤16 as a definition, and in only one report
(29) the authors did not specify their definition albeit reported a
rate. The rationale for combining such heterogenous dichotomous
outcomes in a meta-analysis was that patients qualifying for a
larger percent reduction (e.g., 40%) also simultaneously qualify
for lesser percent reductions (e.g., 25% or 30%); thus one could
be considering all “responding” patients to at least qualify for the
least reported percent reduction. Three studies reported rates for
CY-BOCS ≤11, which was defined as remission in all three. One
study (26) did not specifically report the above-mentioned rates,
but the raw data were included in the published article, which
allowed appropriate calculations to be made.
Altogether 39.5% of patients involved in the 12 RCTs
responded to all forms of treatment (intervention and placebo)
as defined by the variety of numerical cutoffs (25%, 30%, and
40% CY-BOCS reduction, CY-BOCS ≤16 and not otherwise
specified), and 6.4% were considered to have achieved remission
(as defined by CY-BOCS ≤11). The characteristics of included
studies and their participants are presented in further detail in
Tables 1 and 2, respectively. Table 3 presents the risk of bias
assessments across all included studies.

Eligibility for Inclusion

The studies were included if they successfully fulfilled any of the
following criteria:
1. Participants were 18 years or younger
2. Participants had a primary diagnosis of OCD
3. SSRIs, such as escitalopram, fluoxetine, fluvoxamine, paroxetine,
sertraline, vilazodone, and citalopram, were used
4. OCD symptom severity was reported via appropriate
psychometric scale, i.e., CY-BOCS
5. RCTs
6. Studies published in English

Data Synthesis

Change from baseline CY-BOCS, end-treatment CY-BOCS,
and remission and response rates was compared for different
interventions arms. Cochrane’s Review Manager software was used
to perform effect size calculations via random effects model, and
standard mean differences (SMDs) were presented for continuous
and in odds ratios (ORs) for dichotomous outcomes, respectively.
Forest plots and corresponding mean differences were presented in
the figures and tables, where appropriate. A subgroup comparison
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change, 25%red mean,
30%red, CYBOCS ≤ 16 mean,
30%red, rem
III-R
IV
IV

Frontiers in Psychiatry | www.frontiersin.org

Since the meta-analyses performed in this review included less
than 10 studies (see SSRI vs. placebo, N = 7) and were constructed
on random effects model, funnel plots, and trim and fill analyses
[see Refs. (34, 35)] would not be useful to assess publication bias.
Instead, the file drawer phenomenon was recognized, and the
possibility of publication bias was tested via Orwin’s fail-safe N
formula [see below and Ref. (36)].

*All were RCTs.
**A crossover trial.
***All related to CY-BOCS score: mean = end - treatment mean score, change = change from baseline score; red = reduction from baseline score, rem = remission (i.e. end treatment CY-BOCS ≤11). Where missing in the articles, the
data were either calculated from other reported values or, where appropriate, previous meta-analyses were consulted. ITT, intention to treat.
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Alaghband-Rad and
Hakimshooshtary (28)
Asbahr et al. (27)

Diagnosis based
on DSM
Study*

TABLE 1 | Characteristics of included studies.

Pre-trial treatment

Intervention

Control

SSRI

Dose (mg)

Treatment
Duration
(weeks)

Reported Outcome***

ITT

Kotapati et al.

N fs =

N 0 (d0 − dc )
dc − d fs

Because the only meta-analysis performed in this review that
utilizes change from baseline for comparison was that for SSRI
vs. placebo, the decision was made to calculate Nfs only with
data from that analysis. The other analyses in this review used
end-treatment scores for comparison, which by far is not the
most appropriate manner of demonstrating effect size and is not
recommended by Cochrane Handbook for Systematic Reviews
of Interventions (version 5.1.0).
However, the following values were inserted into the formula
above: N0 = 7, d0 = −0.43, dc = 0.2 (since the effect size of the
analysis, by the rule of thumb, was designated as small), and
dfs = 0.
The calculation followed that Nfs = 8 studies with reported
CY-BOCS standardized mean difference of 0.2 (small effect size,
opposite direction) were required to bring the current SMD from
−0.43 to 0.

COMPARISONS
Monotherapy With SSRI Versus Placebo

There were seven RCTs comparing SSRIs with placebo treatment
included in our review. One of them (25) was conducted in a
crossover fashion and only data from the first phase (first 8
weeks) of the study were extracted and analyzed. The reason for
this decision was that after the crossover, 50% of initially enrolled
patients dropped out for reasons such as recurrence of symptoms
after switching to placebo, and the sample size became too small.
For similar reasons and also to yield homogenous treatment
durations only data from the “acute phase” (i.e., the first 8 weeks)
of another study (29) were incorporated into our analysis (the
study also presented data from a later “maintenance phase,”
which lasted for another 8 weeks and was performed with only
participants who were responders). Another study (4) compared
four intervention arms (SSRI, CBT, SSRI + CBT, placebo),
from which we included the data for SSRI and placebo into our
analysis. Overall, we analyzed data on a total number of 725
patients, 51.6% and 48.4% of which received SSRI and placebo,
respectively. All studies except one (4) either reported data on
mean and SD of change from baseline CY-BOCS or presented
other valuable data (t, p, baseline, end-treatment scores), and
the change and SD were calculated in the following manner: the
available values were entered into Rev Man Software’s built-in
calculator, which returned the desirable measures. The mean
differences and their pooled analysis are shown in Table 4.

4

August 2019 | Volume 10 | Article 523

Study

Arms

N (arms)

Male %

Mean age
(SD)

Mean age at
onset

Baseline
CY-BOCS

Completed
the study
(%)

Responders* (%)

Remission**
(%)

Alaghband-Rad and
Hakimshooshtary (28)

29

Fluoxetine

15

58.6

14 ± 2.4

NR

26.7 ± NR

82.8

NR

NR

Asbahr et al. (27)

40

13 ± 2.5

9 ± 3.2

103

47.6

11 ± 2.9

NR

Geller et al. (31)

203

57.6

11 ± 3

8 ± 3.1

Liebowitz et al. (29)

43

58.1

13 ± 2.7

NR

March and Friesen (32)

187

NR

13 ± NR

8 ± NR

Neziroglu et al. (26)

10

60.0

15 ± 2.4

10 ± NR

POTS (4)

112

50.0

12 ± 2.7

NR

Riddle et al. (25)**

14

42.9

12 ± 2.3

NR

Riddle et al. (33)

120

53.3

13 ± NR

9.4 ± NR

Skarphedinsson et al. (18)

50

48.0

14 ± 2.7

NR

Storch et al. (24)

47

14
20
20
71
32
98
105
21
22
92
95
5
5
28
28
28
28
7
7
57
63
22
28
14
17
16

65.0

Geller et al. (30)

Citalopram
SSRI
CBT
SSRI
Placebo
SSRI
Placebo
SSRI
Placebo
SSRI
Placebo
SSRI + CBT
SSRI
CBT
SSRI
SSRI + CBT
Placebo
SSRI
Placebo
SSRI
Placebo
SSRI
CBT
reg SSRI + CBT
slow SSRI + CBT
Placebo + CBT

61.7

14 ± 2.7

NR

TOTAL

958

NR
90.0
95.0
49.3
25.0
62.2
40.0
57.1
31.8
53.3
36.8
40.0 / 80.0*
0.0 / 20.0*
NR
NR
NR
NR
NR
NR
42.1
27.0
45.5 / 45.5*
35.7 / 50.0*
57.1
64.7
62.5
39.5 %***

NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
0.0
0.0
39.3
21.4
53.6
3.6
NR
NR
NR
NR
27.3
32.1
42.9
26.5
18.8
6.4

5

N (size)

43.7

28.0 ± NR
27.0 ± 6.7
26.3 ± 4.9
24.5 ± 5.1
26.3 ± 4.6
24.4 ± 5.0
25.3 ± 5.1
22.5 ± 4.2
23.8 ± 5.8
23.4 ± 4.6
22.2 ± 6.2
28.0 ± 5.6
22.8 ± 3.8
26.0 ± 4.7
23.5 ± 4.7
23.8 ± 3.0
25.2 ± 3.3
24.3 ± 4.2
20.2 ± 7.7
24.2 ± 4.4
24.2 ± 4.8
21.1 ± 3.7
21.3 ± 4.0
23.6 ± 4.5
26.7 ± 5.7
25.1 ± 4.0

97.5
67.0
71.4
88.4
83.4
100.0
86.6

92.9
61.7
72.0
70.2

76.6
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NR, not reported.
Where missing in the articles, the data were either calculated from other reported values or, where appropriate, previous meta-analyses were consulted.
*Responders were defined differently across studies: 25% reduction of CY-BOCS from baseline (27, 31–33), 30% reduction from baseline (18, 24) 40% reduction from baseline (30), end-treatment CY-BOCS ≤ 16 (18), and not
otherwise specified (29). Neziroglu et al. (26) did not specifically report response and remission rates, which were calculated from the raw data and 25 % or 30% reductions/CY-BOCS ≤16 are presented in the corresponding row. 30%
reduction/CY-BOCS ≤16 are presented for the row of Skarphedinsson et al. (18).
**Remission was defined as CY-BOCS ≤11.
***Only 30% reduction rates were taken into account for Neziroglu et al. and Skarphedinsson et al.
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TABLE 2 | Characteristics of participants from included studies.
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TABLE 3 | Risk of bias assessment.
Study

Random
Sequence
Generation

Allocation
Concealment

Blinding of
Participants/
Personnel

Blinding
Outcome
Assessors

Incomplete
Outcome
Data

Selective
Reporting

Other Bias

?

?

?

?

-

-

-

?
?
+
?
+
?
+
?
?
+
+

?
?
?
?
?
?
+
+
?
+
+

?
?
?
+
?
+
+
?

?
?
+
?
?
+
?
+
?
+

+
+
+
+
+
?
+
+
+
+

+
+
+
+
+
+
+
+
+
+

+
+
+
+
+
+
+
+

Alaghband-Rad and
Hakimshooshtary (28)
Asbahr et al. (27)
Geller et al. (30)
Geller et al. (31)
Liebowitz et al. (29)
March and Friesen (32)
Neziroglu et al. (26)
POTS (4)
Riddle et al. (25)**
Riddle et al. (33)
Skarphedinsson et al. (18)
Storch et al. (24)

+
+

“+” is of low risk; “-”is of high risk; “?” is of unclear risk.

TABLE 4 | SSRI vs Placebo.
Name

Size

SSRI

Mean difference [95% CI]

Geller et al. (30)
Liebowitz et al. (29)
Riddle et al. (25)
March and Friesen (32)
POTS (4) *
Geller et al. (31)
Riddle et al. (33)
Total

103
43
14
187
56
203
120
669**

Fluoxetine
Fluoxetine
Fluoxetine
Sertraline
Sertraline
Paroxetine
Fluvoxamine

−4.30 [−7.64 to −0.96]
−2.50 [-7.64, 2.64]
−5.30 [-12.60, 2.00]
−3.40 [-5.74, -1.06]
−5.0 [−8.92 to −1.08]*
−3.40 [−5.60 to −1.20]
−2.70 [−5.39 to −0.01]
−3.38 [−4.60 to −2.16]**

Articles identified through search
in PubMed, Psych INFO, Scopus,
CINAHL and Google Scholar

(N = 1188)
(N = 3429)

Mean differences of change from baseline CY-BOCS.
*The change from baseline SD could not be retrieved or otherwise calculated for POTS
(4); thus, mean difference of end-treatment CY-BOCS was provided.
**The pooled size and mean difference were calculated omitting POTS (4) data.

The studies demonstrated effect sizes (SMD) ranging from small
(−0.28, 95% CI, −0.9 to 0.3) to moderate (−0.75; 95% CI, −1.9 to
0.4), and the pooled analysis achieved a small effect size of −0.43
(95% CI, −0.6 to −0.3), which was significant (see Figure 2),
favoring SSRI. The subgroup analysis did not demonstrate any
difference between different SSRIs. The subgroups of sertraline,
fluoxetine, and other SSRIs (paroxetine and fluvoxamine) all
achieved similar small pooled effect sizes of −0.45 (95% CI, −0.73
to −0.21), −0.45 (95% CI, −0.78 to −0.12), and −0.40 (95% CI,
−0.62 to −0.18), respectively, which did not differ significantly
(Chi2 = 0.18, df = 2 (P = 0.91), I2 = 0%).
Five studies also reported response rates, and one study
reported remission rates based on various definitions (see above
and Table 5). The pooled ln OR for response rate was 0.8 (95%
CI, 0.5–1.1), which converts to SMD of 0.5, 95% CI 0.2, 0.8, p <
0.05 (37) yielding a significant moderate effect size and favoring
SSRI (37).

Title and abstract
review

Excluded titles and
abstracts

(N = 2241)

(N = 2105)

Full text review

Full text articles
excluded

(N = 136)
(N = 124)

Included studies
(N = 12)

FIGURE 1 | PRISMA flow-chart.

were pre-treated with CBT for 13 weeks before randomization,
and thus switching to SSRI was compared to continued CBT
over 16 weeks duration. Another study compared group CBT
(GCBT) and SSRI treatment during 12 weeks (27). The third
study (4), as mentioned above, separately compared three
intervention arms with placebo. Data extracted from the SSRI
and CBT arms were used for comparison. The SDs of change
from baseline were not available for all three studies; thus,

Monotherapy With SSRI Versus CBT

We have identified three RCTs comparing these two treatment
modalities, all utilizing sertraline. In one study where the author’s
randomized patients to either SSRI or CBT (18), all patients
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Excluded duplicates

6

August 2019 | Volume 10 | Article 523

Kotapati et al.

SSRI for Treatment of OCD in Adolescents and Children

FIGURE 2 | SSRI vs. placebo. Standardized mean differences of change from baseline CY-BOCS.

comparison was made utilizing the end treatment CY-BOCS
scores. The two studies (4, 27) showed a mean difference of
2.5 (95% CI, –1.96 to 6.96) and 2.5 (95% CI, –2.37 to 7.37)
in favor of CBT with small effect sizes: SMD = 0.34 (95% CI,
–0.28 to 0.97) and 0.27 (95% CI, –0.26 to 0.79), respectively,
which were not significant. The study by Skarphedinsson et al.
favored SSRI with a mean difference of –1.95 (95% CI, –6.33
to 2.43) and a small effect size of –0.25 (95% CI, –0.81, 0.31),
which was not significant (18). The pooled analysis of the three
studies found a mean difference of 0.92, 95% CI: −2.05, 3.88,
g = 0.11, 95% CI: −0.25, 0.47, which was not significant albeit
weakly favoring CBT (see Figure 3). The studies were also

TABLE 5 | SSRI vs Placebo. Response and remission rates.
Study

Response rates
Geller et al. (30)
Liebowitz et al. (29)
March and
Friesen (32)
Geller et al. (31)
Riddle et al. (33)
Total
Remission rates
POTS

Definition

Size
(N)

ln OR, [95% CI]

P value

40% reduction
NOS
25% reduction

103
43
187

1.1 [0.2, 2.0]
0.9 [0.3, 1.5]
1.1 [−0.2, 2.3]

0.02
0.002
0.1

25% reduction
25% reduction

203
120
656

0.7 [0.1–1.3]
0.7 [−0.1 to 1.4]
0.8 [0.5–1.1]

0.02
0.08
<0.05

CY-BOCS ≤11

56

2.0 [−0.2 to 4.2]

0.07

FIGURE 3 | SSRI vs CBT. Standardized mean differences based on end-treatment CY-BOCS.
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CBT + placebo arms with an effect size of −0.02, 95% CI: −0.74,
0.69 (24). The titration arm showed MD = 1.6; (95% CI, −3.3
to 6.5; SMD, −0.2; 95% CI, −0.5 to 0.9). Both findings were
non-significant. The POTS study achieved a mean difference of
−2.8 (95% CI, −7.6 to 2.0), which was of small effect size, albeit
insignificant (SMD = −0.3, 95% CI, −0.83 to 0.22) (4). A pooled
analysis of the data from POTS and titration arm of Storch et
al., utilizing the random effects model (as the Storch et al. study
did not actually use CBT monotherapy but CBT + placebo)
achieved a mean difference of −0.6 (95% CI, −4.9, 3.7) and effect
size of −0.1 (95% CI, −0.6, 0.4, thus demonstrating no significant
difference (4, 24).

TABLE 6 | SSRI vs CBT. Response and Remission Rates.
Study

Response rate
Asbahr et al. (27)
Skarphedinsson
et al. (18)
Total
Remission rate
Skarphedinsson
et al. (18)
POTS (4)
Total

Definition

Size
(N)

ln OR, [95% CI]

P
value

25% reduction
30% reduction

40
50

−0.7 [−3.2 to 1.7]
0.4 [−0.7 to 1.5]

0.6
0.5

90

0.2 [−0.8 to 1.2]

0.5

CY-BOCS ≤11

50

−0.2 [−1.5 to 1.0

0.7

CY-BOCS ≤11

56

−0.9 [−2.0 to 0.3]
−0.6 [−1.4, 0.3]

0.15
0.2

Combined Therapy With SSRI and CBT
Versus SSRI Alone

compared with regard to their response and remission rates
(see Table 6). Asbahr et al. and Skarphedinsson et al. reported
response rates as defined by 25% and 30% reductions from
baseline CY-BOCS scores, respectively (18, 27). The ln OR for
the two studies were –0.7 (95% CI, –3.2 to 1.7) and 0.4 (95% CI
–0.7 to 1.5), respectively. The combined ln OR was 0.2 (95% CI,
–0.8 to 1.2), weakly favoring SSRI. Skarphedinsson et al. and
POTS presented remission rates of ln OR = –0.2 (95% CI, –1.5
to 1.0; and –0.9 (95% CI, −2.0 to 0.3); respectively, as defined
by end-treatment CY-BOCS ≤11 (4, 18). The combined ln OR
was −0.6 (95% CI, −1.4 to 0.3), which weakly favors CBT. Both
comparisons were statistically non-significant (P > 0.05).

Two studies (4, 26) compared the combination of SSRI and
CBT with SSRI monotherapy. Both reported end-treatment
CY-BOCS data. The study by Neziroglu et al. specifically
compared the combination treatment with monotherapy in a
population that has previously failed CBT monotherapy (26).
The authors evaluated the benefit of adding CBT on SSRI
treatment regimen. Raw data were available and included the
end-treatment CY-BOCS for baseline, 10, 43, and 52 weeks,
and at 2 years follow-up, and change scores. To encompass
homogenous treatment durations the comparison was made
using data from the 52nd week. A mean difference of −5.4
(95% CI, −11.3, 0.5 was observed with a significant, large effect
size of SMD, −1.0, (95% CI: −2.4 to 0.4). The POTS study
yielded a mean difference of −5.3, 95% CI: −10.0, −0.7 with
a moderate effect size of −0.6, 95% CI: −1.1, −0.1, which was
significant (4). The pooled analysis of data from both studies
comprising a total of 66 patients achieved a mean difference
of −5.3 (95% CI, −9.0 to −1.7), which was significant and of
moderate effect size (SMD = −0.7, 95% CI: −1.1, −0.2), thus
favoring the combination treatment.

Combined Therapy With SSRI and CBT
Versus Placebo

From studies included in our review, only one study (4) undertook
a comparison of combination treatment versus placebo. The SD
values of change from baseline could not be extracted from the
paper or retrieved otherwise. Thus, only the end-treatment mean
CY-BOCS could be compared.
The combination treatment and placebo arms yielded scores
of 11.2 (SD = 8.6) and 21.5 (SD = 5.4), respectively, and the mean
difference (MD) of these scores demonstrated the combination
to be significantly superior (MD = −10.3, 95% CI, −14.1 to −6.5)
compared with placebo (SMD = −1.41, 95% CI, −2.0 to −0.82).
The paper also provided data regarding remission rates as defined
by achieved CY-BOCS ≤11 with odds ratio of 31.1 (ln OR = 3.4;
95% CI, 1.3–5.6) and 50% risk difference, which were statistically
significant (P < 0.05).

Comparison of SSRI Versus No SSRI
Intervention Arms

Considering placebo to be not an “actual intervention,” it was
suggested that a comparison could be made between treatment
arms that did or did not use SSRI. Four studies suitable for
such analysis were reported [Refs. (4, 18, 24, 27)]. All four used
sertraline as the SSRI of intervention. Three compared SSRI and
CBT monotherapies, and two compared the combination of
SSRI and CBT with CBT monotherapy (see Table 7). A pooled
analysis of the mean differences using generic inverse variance
and random effects analysis model demonstrated no significant
difference between the two interventions (MD = 0.26, 95% CI, −1.7
to 2.2) (see Figure 4).

Combined Therapy With SSRI and CBT
Versus CBT Alone

Only two studies (4, 24) presented outcomes for comparing SSRI
and CBT combination and CBT monotherapy. Both studies used
sertraline as the intervention medication and reported outcomes as
end-treatment CY-BOCS scores. In the study by Storch et al., CBT
was combined with placebo, and not used as actual monotherapy
(24). The study involved two arms: one with regular dosing and the
other with titrated dosing. The titration arm was used to compare
to the POTS study, which only used the dose titration approach.
In the study by Storch et al., a mean difference of −0.2
(95% C,: −6.2 to 5.8) was observed between the regular and
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Contrary to the comparison above, another suggestion was
made to make a comparison in a similar fashion but including

8

August 2019 | Volume 10 | Article 523

Kotapati et al.

SSRI for Treatment of OCD in Adolescents and Children

Comparison of Different SSRIs

TABLE 7 | Effect sizes for studies comparing SSRI versus no SSRI
interventions.
Name

SSRI vs CBT
Asbahr et al. (27)
POTS (4)
Skarphedinsson et al. (18)
SSRI + CBT vs CBT
POTS (4)
Storch et al. (24)
Storch et al. (24)
SSRI vs Placebo
Geller et al. (30)
Geller et al. (31)
Liebowitz et al. (29)
March and Friesen (32)
POTS (4)
Riddle et al. (25)
Riddle et al. (33)
SSRI + CBT vs Placebo
POTS (4)

Size

SSRI

Effect size: SMD
[95% CI]

40
56
50

Sertraline
Sertraline
Sertraline

0.34 [-0.28, 0.97]
0.27 [-0.26, 0.79]
-0.25 [-0.81, 0.31]

56
33*
30*

Sertraline
Sertraline, titrated
Sertraline, regular

-0.30 [-0.83, 0.22]
0.22 [-0.47, 0.90]
-0.02 [-0.74, 0.69]

103
203
43
187
56
14
120

Fluoxetine
Paroxetine
Fluoxetine
Sertraline
Sertraline
Fluoxetine
Fluvoxamine

-0.49 [-0.91, -0.07]
-0.42 [-0.70, -0.15]
-0.28 [-0.89, 0.32]
-0.42 [-0.71, -0.13]
-0.66 [-1.20, -0.12]
-0.75 [-1.89, 0.39]
-0.36 [-0.72, 0.00]

56

Sertraline

-1.41 [-2.00, -0.82]

None of the identified studies utilized head-to-head design to
directly compare outcomes of different SSRI treatments. Data
of end-treatment CY-BOCS scores from all available studies
reporting a treatment arm of SSRI monotherapy were compared
using generic inverse variance and random analysis model (see
Figure 6). Four studies were using sertraline (4, 18, 27, 32),
four studies using fluoxetine (25, 28–30), two studies using
fluvoxamine (26, 33), one study using paroxetine (31), and one
study using citalopram (28). The standard deviations or errors
were reported in all articles except in Alaghband et al., for
which the reported p values (<0.001 for both arms) were used to
ascertain the possible t values from the t tables and to calculate
the standard errors with Rev Man calculator (28). The estimated
t and p values for fluoxetine and citalopram were t = 4.54, p =
0.0005 and t = 4.57, p = 0.0005, respectively. These converted to
standard errors of SE = 3.3 and SE = 3.7, respectively.
The pooled results of studies that used the same SSRI were
compared visually, and any gross differences (exceeding 2
points on CY-BOCS) were evaluated via the I2 statistic (which
is incorporated in Rev Man). This was facilitated by unchecking
all the other subgroups not to be compared. The two largest
subgroups, namely, the sertraline and fluoxetine, encompassing
four studies each, appeared to achieve similar results (endtreatment mean CY-BOCS = 14.8 (95% CI, 12.5–17.1; and 14.7,
95% CI: 13.0, 16.4; respectively). The largest grossly visualized
difference was detected between subgroups of fluoxetine and
fluvoxamine (14.7, 95% CI: 13.0, 16.4; 18.5; 95% CI, 16.6 to
20.4; respectively), mandating an evaluation of heterogeneity
between them. Once the other subgroups were unchecked
from Rev Man, the test for subgroup differences displayed as:

*These represent summation of arms (SSRI + placebo) and both share the same
placebo control group (i.e. 14 + 16 and 17 + 16).

placebo as an “intervention” (see later in the discussions).
Data from SSRI vs. Placebo comparison were added to the
previous generic inverse variance analysis. The SSRI + CBT vs.
Placebo arm of POTS study was not included in the analysis, as
having a large effect size (SMD = −1.4, 95% CI: −2.0, −0.8) would
clearly deviate the results. The pooled analysis demonstrated a
mean difference of −2.3, 95% CI, −3.6 to −1.1, which was of small
size, albeit significant (see Figure 5).

FIGURE 4 | Comparison of interventions with SSRI and with no SSRI. A generic inverse variance analysis.

Frontiers in Psychiatry | www.frontiersin.org

9

August 2019 | Volume 10 | Article 523

Kotapati et al.

SSRI for Treatment of OCD in Adolescents and Children

FIGURE 5 | Comparison of interventions with SSRI versus all interventions without SSRI, A generic inverse variance analysis.

Chi2 = 8.64, df = 1 (P = 0.003), I2 = 88.4%, where the I2 statistic
notifies of considerable heterogeneity, suggesting a possibility
of fluoxetine’s superiority. Similar findings were noted when
attempting to compare sertraline and fluvoxamine in the same
manner, again suggesting Sertraline’s superiority [Chi2 = 5.87,
df = 1 (P = 0.02), I2 = 83.0%]. The I2 statistic displayed 0 for
all other possible subgroup comparisons carried out in the
same fashion.

be designated as response (in this scenario such reduction
constitutes 14% and grossly differs from those defined in the
literature, e.g. 25%, 30%, 40% reduction or CY-BOCS ≤16). Since
the RCTs were conducted in a mean time period of 8 weeks, the
observed effect represents only the short-term finding. Further
studies with longer trial durations are required to assess the longterm effects and benefits of SSRI monotherapy.
Using the method put forward by Chinn (37), the pooled
response rate transforms to SMD of 0.5, which in contrary to that
seen in continuous outcomes, is already of moderate effect size.
Summarizing the findings of dichotomous outcome comparison,
it suffices to note, that the implicated definitions of 25%, 30%,
or 40% reductions do not necessarily mean clinically significant
symptom reduction but represent more conservative cutoffs to
define minimal observable change (37). By far, the achieved 20%
absolute risk reduction (RD) converts to a number needed to treat
(NOT) of five patients, which could be interpreted as follows: one
would need to treat five patients to achieve minimal clinically
noticeable change in a single patient. Similar to response rates are
those regarding remission, as defined CY-BOCS ≤11. Although
reported in only one study, the absolute risk difference of

DISCUSSIONS
Summary of Main Results SSRI Versus
Placebo

SSRIs are clearly effective compared to placebo for treating OCD
in adolescents and children, but the effect size is small (SMD =
−0.43), which converts to 3.5-point reduction in the CY-BOCS
score. The clinical implication of this finding is hard to evaluate,
as even though the change is statistically significant, some 3.5
points reduced from the initial CY-BOCS of 25 is merely little
symptom reduction to a score of 21.5, which by no means can
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FIGURE 6 | Comparison of SSRI end-treatment CY-BOCS scores. A generic inverse variance analysis.

remission was 18%, which converts to NNT = 6 patients, which
is somewhat consistent with that of response, adding a valuable
notice, which for each six treated patients, one will respond
and another one will probably experience remission. The lack
of studies evaluating remission rates in SSRI vs. Placebo design
limits the value of the later statement. The observed effect size for
children and adolescents is somewhat similar to those reported
in treatment trials of adults with OCD (38).
The reported findings across studies are overall reliable, as
judged from risk of bias, albeit heterogeneous. The interpretations
regarding the effectiveness of SSRI versus Placebo presented above
are mainly consistent with those previously stated (21, 22, 39).
Future studies with the mentioned design are less probable, the
reason being twofold. First, being superior over placebo does not
yet advocate for the intervention’s clinical implications, especially
when an even more effective treatment option clearly exists. Such
an option, exemplified herein by CBT, has been fairly validated,
and its efficacy in children and adolescents has been confirmed
multiple times by various studies (11, 20, 21, 40–42). Second,
leaving the “placebo” arms of children untreated for the study
duration would be somewhat unethical. It is generally considered,

Frontiers in Psychiatry | www.frontiersin.org

that a comparison of this or that intervention with the current
“gold standard” treatment would be far more appropriate in such
settings. This has been clearly stated in the clinical epidemiology
textbook by Haynes (43). It is expected that further research
examining the efficacy of SSRIs in OCD treatment would more
commonly use SSRI vs. CBT design, or evaluate the added benefit
of SSRIs (e.g., SSRI + CBT vs. CBT), as discussed below.

The Effectiveness of SSRI in Other
Comparisons

The only study comparing the combination of SSRI and CBT
with placebo (4) found the former to be highly effective, with
a mean CY-BOCS reduction of 10, which in clinical practice
obviously would make a difference: bringing the CY-BOCS of
a patient from 25 to 15 would denote both clinically important
symptom reduction and match the definition of “response,”
albeit not that of “remission” (4). Also, a 50% risk reduction
was observed for remission, which transforms into NNT = 2.
Despite these findings, only the end-treatment scores were
compared instead of change scores. Thus, the validity of the finding
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cannot be ascertained. Besides, clinicians do not usually prescribe
placebos to proudly state that the combination is superior to it,
neither is the comparison of any value, as both CBT and SSRI are
interventions and both could have contributed to the change, and
the study cannot distinguish the input effect of each. As stated
above, few studies of such designs are expected in the future.
There were two studies comparing the combination to SSRI
monotherapy (4, 26) and two studies comparing it to CBT
monotherapy (4, 24). A significant benefit was observed when
adding CBT to SSRI treatment (with a mean five-point difference
in CY-BOCS), but no significant difference after adding SSRI to
CBT treatment. Both findings point to the superiority of CBT
monotherapy and question the value of adding SSRI to the
already effective treatment regimen with no additional benefit. In
contrast to these findings, the pooled analysis of the three trials
with a head-to-head comparison of SSRI and CBT (4, 18, 27) did
not find any significant difference between the treatment options,
albeit two studies weakly favored CBT, and one weakly favored
SSRI. All three demonstrated small effect sizes. These findings
raise the possibility that SSRI and CBT could be equally effective
options, to begin with, but if the initial treatment is chosen to
be CBT, adding an SSRI regimen would not have additive effect,
although if the SSRI was the option to begin with, adding CBT
sessions would be beneficial to the already “responsive” patient.
The limitation regarding trial duration is as well relevant here,
and the question “which treatment option would hold the benefit
for the longest period” is of important clinical implication.
The findings summarized above are mainly consistent with
observations from adult studies (23). We conclude that SSRI
and CBT could be equal options regarding initial effectiveness,
which somewhat differs from the previous meta-analysis (39),
although we appreciate the large effect sizes that CBT contributes
to outcomes in various study designs.

thus setting soil for future investigations and direct comparisons.
Overall the findings suggested the similar efficacy of fluoxetine
and sertraline and favored these two over fluvoxamine, based on
considerable effect size heterogeneity. As already mentioned, this
does not replace direct comparisons, which are expected to take
place in the future in part by RCTs probably receiving funding by
pharmaceutical companies.

LIMITATIONS
The most important limitation is the paucity of studies
incorporated into meta-analyses, which clearly prevents the
use of more sophisticated research tools and publication bias
reporting with funnel plots and trims and fill technique. The
limitation of excluding non-English studies is also recognized.

CONCLUSIONS
The authors conclude that the results of current systematic
review and meta-analysis support the existing NICE guidelines
for choosing CBT as the first line of treatment or substituting
it with an SSRI for patient preference matters, as both options
seem to be equally effective and the choice rather depends on
patient compliance with either option. Adding CBT to current
SSRI treatment is an effective option for non-responders and
partial responders but adding SSRI to ongoing CBT does not
hold a significant benefit. The SSRIs have different effectiveness,
and their relative efficacy remains to be investigated.

FUTURE RESEARCH
Head-to-head studies are required to evaluate the relative efficacy
of different SSRIs, and a number of new direct studies are needed
to compare SSRIs and CBT. Considering the interesting outcomes
of group CBT, further studies should evaluate this intervention.
The reported outcomes are expected to include pre- and posttreatment CY-BOCS scores, change from baseline and respective
standard deviations, response and remission rates, with more
homogenous definitions. A research guide from authorities for
investigating treatment in children and adolescents with OCD
would be appropriate and of great help to settle such reporting
discrepancies. Regulations regarding study duration would also
contribute to the future research to evaluate the long-term effects
of different treatment regimens, which by all means remains
uninvestigated in children and adolescents with OCD.

Overall Effectiveness of SSRIs

To evaluate the overall effect of SSRIs across various treatment
regimens, the effect sizes of all comparisons made between arms
that involved an SSRI and those without an SSRI were entered
into a generic inverse variance analysis. At first, placebos were not
considered, and the overall benefit of SSRIs across four studies [6
comparisons, 2 intervention arms in each of Storch et al. (24); and
POTS (4)] did not reach significance, but after adding the studies
comparing SSRI to placebo, a small, albeit significant difference
was noted (4, 24). The interpretation of such findings is difficult.
The authors concluded that the overall effectiveness is small and
is mostly seen in studies comparing to placebo. The findings are
consistent with the common clinical scenario, where prescribing
an SSRI to a child with OCD, who is already receiving CBT, does
not improve symptoms significantly over the course of 8 weeks
and continued CBT.
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Differences in SSRI Effectiveness

It suffices to say that the method implemented here was bizarre
and nowhere near a head-to-head comparison or a network metaanalysis, but it was worth entertaining the idea that one SSRI
could be superior over another (e.g., fluoxetine vs. fluvoxamine),
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